Suppressing Hepatic UGT1A1 Increases Plasma Bilirubin, Lowers Plasma Urobilin, Reorganizes Kinase Signaling Pathways and Lipid Species and Improves Fatty Liver Disease

Several population studies have observed lower serum bilirubin levels in patients with non-alcoholic fatty liver disease (NAFLD). Yet, treatments to target this metabolic phenotype have not been explored. Therefore, we designed an N-Acetylgalactosamine (GalNAc) labeled RNAi to target the enzyme that...

Descripción completa

Detalles Bibliográficos
Autores principales: Bates, Evelyn A., Kipp, Zachary A., Martinez, Genesee J., Badmus, Olufunto O., Soundarapandian, Mangala M., Foster, Donald, Xu, Mei, Creeden, Justin F., Greer, Jennifer R., Morris, Andrew J., Stec, David E., Hinds, Terry D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953728/
https://www.ncbi.nlm.nih.gov/pubmed/36830621
http://dx.doi.org/10.3390/biom13020252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953728/
https://www.ncbi.nlm.nih.gov/pubmed/36830621
http://dx.doi.org/10.3390/biom13020252

Ejemplares similares